الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
S
UMMARY
enign prostatic hyperplasia (BPH) refers to the nonmalignant growth or hyperplasia of prostate tissue and is a common cause of lower urinary tract symptoms (LUTS) in men. The development of BPH is characterized by stromal and epithelial cell proliferation in the prostate transition zone leading to compression of the urethra and development of bladder outflow obstruction (BOO) and LUTS.
Treatment options for BPH range from watchful waiting, to medical and surgical intervention.
Tamsulosin is an uro-selective α-1-adrenergic receptor antagonist that demonstrate super-selectivity for α1A-receptors relative to α1B-receptors. The efficacy of Tamsulosin is by blocking α1A adrenoreceptors in the prostate, thereby relaxes the smooth muscles and results in the improvement of the urinary flow rate.
The usual dose is 0.4 mg/day once daily after the breakfast and the dose may be increased to 0.8 mg once daily for the patients who failed to respond the 0.4 mg dose after 2 - 4 weeks of treatment.
A Prospective Interventional Study was held to compare the efficacy and the safety of Tamsulosin 0.4 mg versus Tamsulosin 0.8 mg in patients suffering from LUTS due to BPH. It was carried out on 90 patients who met the criteria and divided
B
Summary
51
randomly and equally into 2 groups. International prostate symptom score (IPSS), Post voiding residual (PVR) urine volume and maximum flow rate (Qmax) of urine were assessed before and after 2 weeks of administering the treatment.
Both study groups showed significant reduction in storage sub score but only frequency was significantly reduced in 0.8 mg group (P < 0.001). On the other hand, Tasmulosin 0.8 mg was superior to Tamsulosin 0.4 mg regarding voiding sub score except for straining (P = 0.325). Accordingly, total IPSS was significantly improved in Tamsulosin 0.8 mg group (P <0.001).
Furthermore, Qmax and PVR urine volume were notably improved with Tamsulosin 0.8 mg compared to Tamsulosin 0.4 mg (P < 0.001).
Although the adverse events such as headache, orthostatic hypotension, and retrograde ejaculation were more frequent, but not significant, to occur with Tamsulosin 0.8 mg, only dizziness was noted to be significant.